In contrast, in a phase I/II trial (NCT01625286), a combination of capivasertib to paclitaxel failed to show improvement of the chemotherapeutic potential of paclitaxel among the patients with PIK3CA-mutated or overall ER +/HER2 − metastatic/progressive breast cancer [103]. This evidence concerns the gene ESR1 and breast cancer.